Welcome to our dedicated page for Whitehawk Therapeutics SEC filings (Ticker: WHWK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Whitehawk Therapeutics, Inc. (Nasdaq: WHWK) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Whitehawk is a clinical-stage oncology therapeutics company focused on antibody-drug conjugate (ADC) cancer treatments, and its filings offer insight into financial results, development plans and corporate activities related to this strategy.
Among the key documents available are current reports on Form 8-K, which Whitehawk has used to furnish press releases announcing quarterly financial results and recent highlights. These filings reference information such as research and development spending, progress toward Investigational New Drug (IND) submissions for ADC programs like HWK-007 and HWK-016, and updates on the company’s three-asset ADC portfolio targeting PTK7, MUC16 and SEZ6.
On this page, users can also locate Whitehawk’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically contain more detailed discussions of the company’s oncology pipeline, risk factors, and financial condition. For investors interested in governance and compensation matters, proxy materials and related filings can provide additional context on board and executive oversight of the ADC development strategy.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand major updates without having to parse every page. Real-time updates from the SEC’s EDGAR system ensure that new WHWK filings, including future 10-Ks, 10-Qs and 8-Ks, appear promptly. Users can also review insider transaction reports on Form 4, when available, to see reported trades by directors and officers.
Together, these resources give a structured view of how Whitehawk reports its financial performance, clinical progress and corporate decisions to regulators and the market.
Whitehawk Therapeutics, Inc. reported the results of its 2026 annual meeting of stockholders, where investors voted on director elections, executive pay and the company’s auditor. A total of 40,375,023 common shares, representing approximately 82% of voting power as of April 17, 2026, were present, establishing a quorum.
Stockholders elected three Class III directors – Behzad Aghazadeh, Ph.D., Richard Maroun and Emma Reeve – to terms ending at the 2029 annual meeting. On an advisory basis, stockholders approved the compensation of named executive officers. They also ratified the appointment of BDO USA, P.C. as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Whitehawk Therapeutics is registering the resale of up to 22,321,887 shares of its common stock. These Shares consist of 4,330,866 outstanding shares and 17,991,021 shares issuable upon exercise of pre-funded warrants sold in a Private Placement closed May 14, 2026. The Company will receive no proceeds from resales under this prospectus and has agreed to bear registration expenses per a Registration Rights Agreement executed with the purchasers. The Private Placement raised approximately $87.5 million at a purchase price of $3.92 per share (and $3.9199 per pre-funded-warrant share), and certain holders are subject to Beneficial Ownership Limitations (4.99%, 9.99% or 19.99%, at holder election).
Whitehawk Therapeutics, Inc. disclosed an option agreement with Hangzhou DAC that expands its antibody-drug conjugate (ADC) pipeline by providing access to the CPT113 linker-payload for use in up to five additional, internally developed ADC programs. Whitehawk will select targets, source antibodies, and retain global rights and full control of these programs, and expects to submit multiple Investigational New Drug applications over the next 12–24 months.
External programs using CPT113, including Hangzhou DAC’s DXC006 and Johnson & Johnson’s JNJ-95437446, have shown early clinical and preclinical data that support continued development of this technology. Whitehawk’s own Phase 1 dose-escalation trials for HWK-007 and HWK-016 are enrolling, with initial data expected in the first half of 2027, while an IND for HWK-206 is anticipated mid-year. The company also highlights typical development, safety, and financing risks that could cause actual outcomes to differ from current expectations.
Acuta Capital Partners and related entities reported significant positions in Whitehawk Therapeutics' common stock in this amended Schedule 13D. Acuta beneficially owns 4,685,912 shares, or 8.7% of the company, while manager Anupam Dalal is deemed to beneficially own 4,843,775 shares, or 9.0%. The Acuta Capital Fund, LP holds 3,538,288 shares, or 6.6%. The funds used a total of $59,388,056.89 of working capital to purchase common stock, including 1,275,510 shares bought directly from the company in a May 14, 2026 private placement at $3.92 per share, of which 1,002,800 shares were purchased by the Partnership. The investors state they acquired the stock for investment purposes and may increase or decrease their holdings or engage in hedging or derivative transactions over time.
Dugan Margaret reported acquisition or exercise transactions in this Form 4 filing.
Whitehawk Therapeutics, Inc. reported that its Chief Medical Officer, Margaret Dugan, received a grant of 19,132 shares of common stock on May 14, 2026. The shares were valued at $3.92 per share for reporting purposes, bringing her direct holdings to 19,132 shares. This is a compensation-related award, not an open-market purchase.
Whitehawk Therapeutics executive Bryan Ball reported a stock-based compensation grant on Common Stock. On May 14, 2026, he acquired 51,020 shares at an indicated value of $3.92 per share as a grant or award, rather than an open-market purchase. Following this award, his direct holdings in Whitehawk Therapeutics increased to 448,126 Common Stock shares, reflecting a routine compensation-related equity grant instead of a discretionary market trade.
Whitehawk Therapeutics, Inc. Chief Financial Officer Scott M. Giacobello reported a compensation-related stock award on a Form 4. He acquired 38,265 shares of common stock on May 14, 2026 in a transaction classified as a grant or award at a reference price of $3.92 per share. Following this award, his directly held ownership increased to 333,489 shares of Whitehawk Therapeutics common stock. This filing reflects an equity grant rather than an open-market purchase or sale.
Whitehawk Therapeutics, Inc. director and chief executive officer David James Lennon reported an equity compensation grant of Common Stock. He acquired 51,021 shares at an indicated value of $3.92 per share as a grant, bringing his direct holdings to 569,643 shares after the transaction.
Whitehawk Therapeutics director Caley Castelein reported new share and warrant awards. He received a grant of 255,102 shares of Common Stock at $3.92 per share, bringing his directly held Common Stock to 274,796 shares.
Entities associated with him, specifically KVP Capital, LP, now hold 2,165,998 shares of Common Stock indirectly and a Pre-Funded Warrant to acquire 2,072,756 additional Common shares at an exercise price of $0.0001 per share. The warrant can be exercised on or after May 14, 2026, but includes a 4.99% beneficial ownership cap. Castelein is Managing Director of KVP Capital and disclaims beneficial ownership in those indirect holdings except for his pecuniary interest.